



November 5, 2020

**VIA EDGAR**

Securities and Exchange Commission  
100 F Street N.E.  
Washington, D.C. 20549-7010  
USA

**Re: InMed Pharmaceuticals Inc.  
Registration Statement on Form S-1  
Filed June 19, 2020, as amended  
File No. 333-239319**

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the "Securities Act"), InMed Pharmaceuticals Inc. (the "Company") hereby respectfully requests that the Securities and Exchange Commission (the "Commission") accelerate the effective date of the above-referenced Registration Statement (the "Registration Statement") to November 9, 2020 at 5:00 p.m. (Eastern) or as soon thereafter as is practicable.

The Company also requests the Commission confirm the effective date and time of the Registration Statement in writing.

**INMED PHARMACEUTICALS INC.**

By \_\_\_\_\_ /s/ Eric A. Adams  
Name: Eric A. Adams  
Title: President & Chief Executive Officer

**InMed Pharmaceuticals Inc, #310-815 West Hastings St., Vancouver, BC, Canada, V6C-1B4  
[www.inmedpharma.com](http://www.inmedpharma.com) Tel. 604.669.7207 Fax. 778.945.6800**